


PHARMACEUTICAL 2017

AKORN INC Rank 36 of 313





PHARMACEUTICAL 2017



AKORN INC Rank 36 of 313

The relative strengths and weaknesses of AKORN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AKORN INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 355% points. The greatest weakness of AKORN INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 119% points.

The company's Economic Capital Ratio, given in the ranking table, is 105%, being 521% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	685,811
Cost of Goods Sold	442,572
Intangible Assets	1,043,147
Liabilities, Current	175,555
Liabilities, Non-Current	978,981
Other Assets	6,358
Other Compr. Net Income	-4,825
Other Expenses	204,444
Other Liabilities	0
Other Net Income	-45,480
Property and Equipment	238,404
Research and Development	42,603
Revenues	1,116,843
Selling, General and Administrative Expense	197,501

Output Variable	Value in 1000 USD
Assets	1,973,720
Liabilities	1,154,536
Expenses	887,120
Stockholders Equity	819,184
Net Income	184,243
Comprehensive Net Income	181,830
Economic Capital Ratio	105%